Amit M. Deshpande

MMAE levels in cynomolgus monkeys following single dosing of MYTX-011, parent and benchmark ADCs.

Cytotoxicity of MYTX-011 across 62 cancer cell lines.

Species cross reactivity of MYTX-011.

Total ADC, total mAb and free MMAE levels following a single dose of MYTX-011. Cynomolgus monkeys (n=3 per group) were dosed with 6.0 mg/kg of the respective test articles and total.

Displays mAb uptake in three cMET+ cell lines.

Binding affinity of MYTX-011 to recombinant cMET and cMET expressed on cells.

Total ADC, total mAb and free MMAE levels following a single dose of MYTX-011. Cynomolgus monkeys (n=3 per group) were dosed with 6.0 mg/kg of the respective test articles and total.

Advances in linker payload technology and target selection have been at the forefront of recent improvements in antibody–drug conjugate (ADC) design, leading to several approvals over the last decade. In contrast, the potential of novel ADC technologies to enhance payload delivery to tumors is relatively underexplored. We demonstrate that incorporation of pH-dependent binding in the antibody component of a c-mesenchymal–epithelial transition (MET)–targeting ADC (MYTX-011) can overcome the requirement for high c-MET expression on tumors, an innovation that has the potential to benefit a broader population of patients with lower c-MET levels. MYTX-011 drove fourfold higher net internalization than a non–pH-engineered parent ADC in non–small cell lung cancer (NSCLC) cells and showed increased cytotoxicity against a panel of cell lines from various solid tumors. A single dose of MYTX-011 showed at least threefold higher efficacy than a benchmark ADC in mouse xenograft models of NSCLC ranging from low to high c-MET expression. Moreover, MYTX-011 showed improved pharmacokinetics over parent and benchmark ADCs. In a repeat dose toxicology study, MYTX-011 exhibited a toxicity profile similar to other monomethyl auristatin E–based ADCs. These results highlight the potential of MYTX-011 for treating a broader range of patients with NSCLC with c-MET expression than other c-MET–targeting ADCs. A first-in-human study is ongoing to determine the safety, tolerability, and preliminary efficacy of MYTX-011 in patients with NSCLC (NCT05652868).